Journal
CELL METABOLISM
Volume 32, Issue 2, Pages 203-+Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2020.04.019
Keywords
-
Categories
Funding
- Intramural Research Program of the National Institute on Aging/NIH
- NIH/NIA [AG031782, AG038072]
- National Medical Health and Research Council of Australia CJ Martin Early Career Fellowship (RGMS) [2010-01671]
- Cancer Institute New South Wales [15/FRL/1-06A]
- NHMRC [APP1120475]
- KRIBB Research Initiative Program (Korean Biomedical Scientist Fellowship Program), Korea Research Institute of Bioscience and Biotechnology, Republic of Korea
- NIH [R35HL135820]
- NATIONAL INSTITUTE ON AGING [ZIAAG000363] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000368] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Obesity is a top public health concern, and a molecule that safely treats obesity is urgently needed. Disulfiram (known commercially as Antabuse), an FDA-approved treatment for chronic alcohol addiction, exhibits anti-inflammatory properties and helps protect against certain types of cancer. Here, we show that in mice disul-firam treatment prevented body weight gain and abrogated the adverse impact of an obesogenic diet on in-sulin responsiveness while mitigating liver steatosis and pancreatic islet hypertrophy. Additionally, disulfiram treatment reversed established diet-induced obesity and metabolic dysfunctions in middle-aged mice. Re-ductions in feeding efficiency and increases in energy expenditure were associated with body weight regu-lation in response to long-term disulfiram treatment. Loss of fat tissue and an increase in liver fenestrations were also observed in rats on disulfiram. Given the potent anti-obesogenic effects in rodents, repurposing disulfiram in the clinic could represent a new strategy to treat obesity and its metabolic comorbidities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available